Phaseline

Companies › Lakefront Biotherapeutics

Lakefront Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jul 2039.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GLPG CAR T-cell therapy
Chimeric antigen receptor (CAR) T-cell therapy
–Phase 3Hematological MalignanciesJul 2039

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06652633GLPG CAR T-cell therapyPhase 3Hematological MalignanciesOncologyJul 2039

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

GT Medical Technologies Suzhou Immunofoco Biotechnology Biofrontera CG Oncology CNBG-Virogin Biotech (Shanghai)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.